Potentially Unfair Tender Offer for Inhibitex Triggers Shareholder-Claim Investigation by Securities Class Action Lawyers at Goldfarb Branham LLP

DALLAS, Jan. 11, 2012/PRNewswire/ -- Securities lawyers at Goldfarb Branham LLP are investigating whether certain officers and directors of Inhibitex, Inc. (NASDAQ: INHX) violated shareholder protection laws by agreeing to a tender offer sale of the company for $26.00in cash per share to Bristol-Myers Squibb. Concerned Inhibitex investors are encouraged to contact class action attorney Hamilton Lindley at 877-583-2855 or hlindley@goldfarbbranham.com about their rights and remedies.

"An analyst has targeted the Inhibitex stock price at $34," said Hamilton Lindley. "While Bristol Myers may be losing patent protection on three of its four top drugs Inhibitex has powerful drugs for Hepatitits C-a $20 billionmarket. Our proposed shareholder lawsuit seeks to ensure that the Inhibitex stockholders receive the most money and information that the law allows."  

Goldfarb Branham LLP lawyers have significant experience representing shareholders and whistleblowers in securities lawsuits nationwide. Inhibitex investors - or anyone with knowledge about this situation - should contact lawyer Hamilton Lindley at hlindley@goldfarbbranham.com or 877-583-2855.

SOURCE Goldfarb Branham LLP

distribué par

Ce noodl a été diffusé par Inhibitex Inc. et initialement mise en ligne sur le site http://www.inhibitex.com. La version originale est disponible ici.

Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-11 19:05:10 PM et restera accessible depuis ce lien permanent.

Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité.